Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) has been assigned a consensus recommendation of “Hold” from the five ratings firms that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, three have issued a hold rating and one has assigned a buy rating to the company. The average […]
Related Keywords
United States , William Blair , Citigroup Inc , Mackenzie Financial Corp , Nektar Therapeutics , Sg Americas Securities , Jefferies Financial Group , Marquette Asset Management , Barclays Plc , Nektar Therapeutics Company Profile , Get Free Report , Financial Group , Financial Corp , Asset Management , Get Free , Nektar Therapeutics Daily , Nasdaq Nktr , Nktr , Medical , 64026810 , Ratings , Consensus ,
comparemela.com © 2020. All Rights Reserved.